Centers for Disease Control.Preventing Lead Poisoning in Young Children. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control; October1991.
2.
Markowitz ME , Rosen JENeed for the lead mobilization test in children with lead poisoning. J Pediatr.1991;119:305-310.
3.
Cory-Slechta DA, Weiss B.Efficacy of the chelating agent CaEDTA in reversing lead-induced changes in behavior. Neurotoxicology.1990;10:685-697.
4.
Chisolm JJ, Harrison HEThe treatment of acute lead encephalopathy in children. Pediatrics.1957;19:2-20.
5.
Ennis JM, Harrison HETreatment of lead encephalopathy with BAL (2.3 dimercaptopropanol) . Pediatrics. 1950;5:853-868.
6.
Cory-Slechta DA, Weiss B., Cox C.Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy . J Pharmacol Exp Ther.1987;243:804-813.
7.
Chisolm JJEvaluation of the potential role of chelation therapy in treatment of low to moderate lead exposures. Environ Health Perspect.1990;89:67-74.
8.
Piomelli S., Rosen JF, et al. Management of childhood lead poisoning. J Pediatr.1984;105:523-532.
9.
Markowitz ME , Rosen JFAssessment of lead stores in children: validation of an 8-hour CaNa2EDTA provocative test. J Pediatr.1984;104:337-341.
10.
Chisolm JJMobilization of lead by calcium disodium edetate: a reappraisal. Am J Dis Child.1987;141:1256-1257.
11.
Weinberger HL, Post EM, et al. An analysis of 248 initial mobilization tests performed on an ambulatory basis. Am J Dis Child.1987;141:1266-1270.
12.
Shannon M., Grace A., Graef J.Use of urinary lead concentration in interpretation of the EDTA mobilization test. Vet Hum Toxicol.1989;32(2):140-142.
13.
Saenger P., Rosen JF, Markowitz M.Diagnostic significance of edetate disodium calcium testing in children with increased lead absorption. Am J Dis Child.1982;136:312-315.
14.
Markowitz ME , Rosen JF, Bijur PEEffects of iron deficiency on lead excretion in children with moderate lead intoxication. J Pediatr.1990 ;116:360-364.
15.
Telfer JGUse ofBAL in lead poisoning. JAMA.1947;135:835-837.
16.
Ryder HW, Cholak J., Kehoe RAInfluence of dithiopropanol (BAL) on human lead metabolism. Science. 1947;105:63-64.
17.
Chisolm JJThe use of chelating agents in the treatment of acute and chronic lead intoxication in childhood. J Pediatr.1968;73:1-38.
18.
Peters RA, Spray GH, Stocken LA, et al. The use of British anti-lewisite containing radioactive sulphur for metabolism investigations. Biochem J.1947;41:370-373.
19.
Spray GH, Stocken LA, Thompson Rhs.Further investigations on the metabolism of 2:3-dimercaptopropanol . Biochem J.1947;41:362-366.
20.
Aronson AL, Hammond PBEffect of two chelation agents on the distribution and excretion of lead. J Pharmacol Exp Ther.1964;146:241-251.
21.
Thomas DJ, Chisolm JJLead, zinc and copper decorporation during calcium disodium ethylenediamine tetraacetate treatment of lead-poisoned children. jPharmacol Exp Ther. 1986;239:829-835.
22.
Perry HM, Perry EFNormal concentrations of some trace metals in human urine: changes produced by ethylenediaminetetraacetate. J Clin Invest.1959;38:1452-1463.
23.
Foreman H., Trujillo TTThe metabolism of C14-labeled ethylenediaminetetra-acetic acid in human beings . J Lab Clin Med.1954;43:566-571.
24.
Jugo S., Maljkovic T., Kostial K.Influence of chelating agents on the gastrointestinal absorption oflead . Toxicol Appl Pharmacol.1975;34:259-263.
25.
Hammond PB, Aronson AL, Olson WCThe mechanism of mobilization of lead by ethylenediaminetetraacetate . J Pharmacol Exp Ther.1967;157:196-206.
26.
Hammond PBThe effects of chelating agents on the tissue distribution and excretion of lead. Toxicol Appl Pharmacol.1971;18:296-310.
Foreman H.Toxic side effects of ethylenediaminetetraacetic acid. J Chron Dis.1963;16:319-323.
29.
Vitale LF, Rosalinas-Bailon A., Folland D., et al. Oral penicillamine therapy for chronic lead poisoning in children . J Pediatr.1973;83:1041-1045.
30.
Chisolm JJChelation therapy in children with subclinical plumbism. Pediatrics. 1974;53:441-443.
31.
Shannon M., Graef J., Lovejoy FHEfficacy and toxicity of D-penicillamine in low-level lead poisoning . J Pediatr.1988;112:799-804.
32.
Hammond PBThe effects of D-penicillamine on the tissue distribution and excretion of lead. Toxicol Appl Pharmacol.1973;26:241-246.
33.
Russell JC, Griffin TB, McChesney EW, et al. Metabolism of airborne particulate lead in continuously exposed rats: effect of penicillamine on mobilization. Exotoxicol Environ Safety.1978;2:49-53.
34.
Rosen JF, Markowitz MED-Penicillamine: its actions on lead transport in bone organ culture . Pediatr Res.1980;14:330-335.
35.
Besunder JB , Reed MD, Fedak MJ, et al. D-Penicillamine pharmacokinetics and pharmacodynamics in lead intoxicated children. Pediatr Res.1989;25(4):65A.
36.
Osman MA, Patel RB, Schuna A., et al. Reduction in oral penicillamine absorption by food, antacid, and ferrous sulfate. Clin Pharmacol Ther.1983;33:465-470.
37.
Ifan A., Welling PGPharmacokinetics of oral 500-mg penicillamine: effect of antacids on absorption . Biopharm Drug Dispos.1986 ;7:401-405.
38.
Bartsocas CS , Grunt JA, Boylen GW, et al. Oral D-penicillamine and intramuscular BAL+EDTA in the treatment of lead accumulation. Acta Paediatr Scand.1971;60:553-558.
39.
Sachs HK, Blanksma LA, Murray EF, et al. Ambulatory treatment of lead poisoning: report of 1,155 cases . Pediatrics. 1970;46:389-396.
40.
Marcus SM: Experience with D-penicillamine in treating lead poisoning. Vet Hum ToxicoL1982;24:18-20.
41.
Friedheim E. , Graziano JH, Popovac D., et al. Treatment of lead poisoning by 2,3-dimercaptosuccinic acid. Lancet. 1978;2:1234-1236.
42.
Graziano JH, Leong JK, Friedheim E.2,3-dimercaptosuccinic acid: a new agent for the treatment of lead poisoning . J Pharmacol Exp Ther.1978;206:696-700.
43.
Graziano JH , Lolacono NJ, Meyer P.Dose-response study of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrations . J Pediatr.1988;113:751-757.
44.
Graziano JH , Lolacono NJ, Moulton T., et al. Controlled study of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxication . J Pediatr.1992;120:133-139.
45.
Cory-Slechta DAMobilization of lead over the course of DMSA chelation therapy and long-term efficacy. jPharmacol Exp Ther. 1988;246:84-91.
46.
Friedheim E. , Corvi C., Wakker CHMeso-dimercaptosuccinic acid: a chelating agent for the treatment of mercury and lead poisoning. J Pharm Pharmacol.1976;28:711-714.
47.
McNeil Consumer Products Company.Chemet: A Summary of Pharmacological and Clinical Data. Seymour, IN: Central Pharmaceuticals; 1991 :8. Monograph.
48.
Maiorino RM , Akins JM, Blaha K., et al. Determination and metabolism of dithiol chelating agents: X. In humans, meso-2,3-dimercaptosuccinic acid is bound to plasma proteins via mixed disulfide formation. J Pharmacol Exp Ther.1990;254:570-577.
49.
Maiorino RM , Bruce DC, Aposhian HV Determination and metabolism of dithiol chelating agents. Toxicol Appl Pharmacol.1989;97:338-349.
50.
Graziano JH , Siris ES, Lolacono N., et al. 2,3-dimercaptosuccinic acid as an antidote for lead intoxication. Clin Pharmacol Ther.1985;37:431-438.
51.
Aposhian HV , Aposhian MMMeso-2, 3-dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Annu RevPharmacol ToxicoL1990;30:279-306.
52.
Mortensen ME , Valenzuela PMDimercaptosuccinic acid (DMSA) chelation for childhood lead poisoning. Clin Pharmacol Ther.1991;49:(2)162.
53.
Kapoor SC, Wielopolski L., Graziano JH, et al. Influence of 2,3-dimercaptosuccinic acid on gastrointestinal lead absorption and whole-body lead retention. Toxicol Appl Pharmacol.1989;97:525-529.
54.
Graziano JHRole of 2,3-dimercaptosuccinic acid in the treatment of heavy metal poisoning. Med Toxicol.1986 ;1:155-162.
